Inactive Instrument

Silence Therapeutics plc London S.E.

Equities

GB0008433350

End-of-day quote London S.E. Other stock markets
- ^GBX	-

05:11pm	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT
Jul. 12	European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	MT

Silence Therapeutics : Departure of Chief Financial Officer

January 09, 2019 at 02:34 am EST

Silence Therapeutics announces departure of Chief Financial Officer

January 9, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ('Silence' or 'the Company') a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces the departure of Mr. David Ellam, its Chief Financial Officer, with immediate effect. Dr Rob Quinn, Silence Therapeutics' Group Head of Financial Planning and Analysis will serve as interim CFO until a new CFO is appointed.

Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:

'On behalf of the Board I would like to thank David for his contribution to Silence. He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space. We wish David every success for the future.'

Enquiries:

Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer	Tel: +44 (0)20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel: +44 (0)20 7418 8900
European IR Consilium Strategic Communications Mary-Jane Elliott / Angela Gray silencetherapeutics@consilium-comms.com	Tel: +44 (0) 20 3709 5700
US IR Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com	Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/

Attachments

Original document
Permalink

Disclaimer

Silence Therapeutics plc published this content on 09 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 09 January 2019 07:33:07 UTC

Latest news about Silence Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	11:11am	MT
European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	Jul. 12	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	Jul. 08	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Jul. 02	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	Jun. 28	MT
Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating	Jun. 28	MT
Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating	Jun. 28	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	Jun. 27	MT
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	Jun. 27	MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	Jun. 27	MT
Silence Therapeutics Says Divesiran Shows Sustained Hematocrit Reduction in Blood Cancer Study	Jun. 27	MT
Transcript : Silence Therapeutics plc - Special Call	Jun. 27
Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients	Jun. 27	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Jun. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	Jun. 21	MT
Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)	Jun. 20	CI
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	Jun. 17	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	Jun. 12	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	May. 30	MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	May. 28	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	May. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	May. 21	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	May. 20	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	May. 17	MT
Silence Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 16	CI

Chart Silence Therapeutics plc

Duration

Period

More charts

Company Profile

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is focused on discovering and developing molecules incorporating short-interfering ribonucleic acid (siRNA) to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body's natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA (mRNA), molecules that encode specific targeted disease-associated proteins in a cell. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target disease-associated genes in the liver. Its wholly owned product candidates include SLN360, for the unmet need in reducing cardiovascular risk in people born with high Lipoprotein (a) levels and SLN124, for rare hematological conditions, including thalassemia, myelodysplastic syndrome (MDS), and polycythemia vera (PV).

Sector

Calendar

2024-09-11 - Q2 2024 Earnings Release (Projected)

More about the company